NASDAQ:AKBA
$1.10
(
0.92%
)
Friday, 2nd Jun 2023
Akebia Therapeutics Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $0.84 | $1.63 | Friday, 2nd Jun 2023 AKBA stock ended at $1.10. This is 0.92% more than the trading day before Thursday, 1st Jun 2023. During the day the stock fluctuated 9.35% from a day low at $1.07 to a day high of $1.17. |
| 90 days | $0.490 | $1.63 | |
| 52 weeks | $0.241 | $1.63 |
Historical Akebia Therapeutics prices
| Date | Open | High | Low | Close | Volume |
| 2023-06-02 | $1.12 | $1.17 | $1.07 | $1.10 | 1 746 673 |
| 2023-06-01 | $1.04 | $1.15 | $1.00 | $1.09 | 3 617 625 |
| 2023-05-31 | $1.12 | $1.10 | $0.98 | $1.04 | 3 977 095 |
| 2023-05-30 | $1.29 | $1.40 | $0.90 | $0.96 | 6 057 511 |
| 2023-05-26 | $1.10 | $1.23 | $1.07 | $1.13 | 2 118 069 |
| 2023-05-25 | $1.39 | $1.40 | $1.14 | $1.21 | 3 603 104 |
| 2023-05-24 | $1.40 | $1.45 | $1.37 | $1.43 | 1 052 569 |
| 2023-05-23 | $1.42 | $1.60 | $1.36 | $1.39 | 2 669 854 |
| 2023-05-22 | $1.26 | $1.63 | $1.26 | $1.41 | 7 708 597 |
| 2023-05-19 | $1.08 | $1.18 | $1.08 | $1.16 | 1 085 387 |
| 2023-05-18 | $1.13 | $1.17 | $1.05 | $1.09 | 776 976 |
| 2023-05-17 | $1.08 | $1.13 | $1.05 | $1.13 | 1 090 642 |
| 2023-05-16 | $1.07 | $1.08 | $1.00 | $1.05 | 1 562 238 |
| 2023-05-15 | $1.10 | $1.19 | $1.05 | $1.09 | 1 717 840 |
| 2023-05-12 | $1.07 | $1.17 | $1.06 | $1.13 | 1 928 646 |
| 2023-05-11 | $1.04 | $1.08 | $1.02 | $1.06 | 1 075 586 |
| 2023-05-10 | $1.06 | $1.06 | $0.98 | $1.03 | 1 504 439 |
| 2023-05-09 | $1.02 | $1.08 | $1.00 | $1.05 | 667 896 |
| 2023-05-08 | $1.08 | $1.09 | $0.94 | $1.06 | 2 662 194 |
| 2023-05-05 | $0.94 | $1.09 | $0.94 | $1.09 | 2 353 866 |
| 2023-05-04 | $0.87 | $0.97 | $0.84 | $0.93 | 1 601 657 |
| 2023-05-03 | $0.89 | $0.91 | $0.87 | $0.88 | 795 017 |
| 2023-05-02 | $0.85 | $0.90 | $0.83 | $0.88 | 496 492 |
| 2023-05-01 | $0.91 | $0.92 | $0.82 | $0.87 | 1 225 357 |
| 2023-04-28 | $0.91 | $0.94 | $0.89 | $0.91 | 1 512 848 |
| 2023-04-27 | $0.83 | $0.91 | $0.80 | $0.91 | 2 140 962 |
| 2023-04-26 | $0.712 | $0.85 | $0.682 | $0.793 | 1 988 374 |
| 2023-04-25 | $0.650 | $0.777 | $0.650 | $0.714 | 2 799 055 |
| 2023-04-24 | $0.650 | $0.700 | $0.650 | $0.671 | 528 681 |
| 2023-04-21 | $0.630 | $0.676 | $0.590 | $0.660 | 760 174 |
| 2023-04-20 | $0.706 | $0.719 | $0.654 | $0.660 | 694 262 |
| 2023-04-19 | $0.662 | $0.740 | $0.660 | $0.723 | 835 536 |
| 2023-04-18 | $0.659 | $0.698 | $0.633 | $0.682 | 716 504 |
| 2023-04-17 | $0.627 | $0.670 | $0.610 | $0.650 | 1 343 010 |
| 2023-04-14 | $0.624 | $0.660 | $0.601 | $0.628 | 406 489 |
| 2023-04-13 | $0.623 | $0.670 | $0.623 | $0.637 | 551 875 |
| 2023-04-12 | $0.660 | $0.660 | $0.600 | $0.623 | 543 308 |
| 2023-04-11 | $0.548 | $0.679 | $0.548 | $0.648 | 1 292 038 |
| 2023-04-10 | $0.540 | $0.590 | $0.532 | $0.569 | 567 633 |
| 2023-04-06 | $0.516 | $0.579 | $0.506 | $0.540 | 736 449 |
| 2023-04-05 | $0.539 | $0.539 | $0.490 | $0.506 | 897 838 |
| 2023-04-04 | $0.582 | $0.582 | $0.521 | $0.539 | 1 234 615 |
| 2023-04-03 | $0.574 | $0.590 | $0.530 | $0.578 | 1 736 488 |
| 2023-03-31 | $0.570 | $0.580 | $0.542 | $0.560 | 1 073 341 |
| 2023-03-30 | $0.600 | $0.611 | $0.551 | $0.563 | 1 194 001 |
| 2023-03-29 | $0.600 | $0.620 | $0.550 | $0.605 | 1 122 274 |
| 2023-03-28 | $0.640 | $0.650 | $0.588 | $0.599 | 1 234 867 |
| 2023-03-27 | $0.620 | $0.660 | $0.611 | $0.656 | 1 066 708 |
| 2023-03-24 | $0.690 | $0.690 | $0.613 | $0.639 | 1 235 633 |
| 2023-03-23 | $0.670 | $0.694 | $0.620 | $0.685 | 991 503 |
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
